EXBIO manufactures and supplies antibodies for world-wide distribution. Sales on an OEM basis and in bulk quantity is the core business activity of the company.
Strong Research & Development (hybridoma technology, construction of recombinant proteins and antibodies) in co-operation with academic institutions ensures the continuous addition of important new products.
EXBIO entered the antibody market as a spin-off company of Czech Academy of Sciences in 1990. Continuous economic growth resulted in the movement to our own brand new manufacture facility on February 2003.
EXBIO participates in European FP7 HEALTH large scale integrating project SYBILLA - Systems Biology of T cell Activation in Health and Disease (2008-2013).